Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety of Degarelix in Prostate Cancer Extension Study
NCT00215657Phase 2Terminated
- Sponsor
- Ferring Pharmaceuticals
- Start
- Mar 2003
- Primary completion
- Mar 2006
- Modality
- Peptides, Small Molecules
01
Overview
A Phase 2 trial of degarelix in prostate cancer (PCa), sponsored by Ferring Pharmaceuticals. Started Mar 2003; status: terminated.
02
Drugs
degarelix
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00215657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00215657.